LEADER 01863nam  2200349   450 
001 9910734347803321
005 20230816094643.0
035   $a(CKB)5470000002907831
035   $a(NjHacI)995470000002907831
035   $a(EXLCZ)995470000002907831
100   $a20230816d2023      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aApplication of Botulinum Neurotoxin in Lower Urinary Tract Dysfunctions $eWhere Are We Now? /$fedited by Hann-Chorng Kuo
210  1$a[Place of publication not identified] :$cMDPI - Multidisciplinary Digital Publishing Institute,$d2023.
215   $a1 online resource (172 pages)
311   $a3-0365-7939-7 
330   $aEvidence has shown that botulinum toxin A has advantages in lower urinary tract dysfunctions (LUTDs), especially in interstitial cystitis, urethral sphincter dysfunction, and inflammatory bladder disorders which currently cannot be adequately treated with oral pharmacological medications. This Special Issue has collected original or review articles that focus on the novel applications of botulinum toxin A in LUTDs. The research has been updated and contains novel therapeutic applications of botulinum toxin for bladder or urethral dysfunctions. This Special Issue of Toxins provides current knowledge surrounding the status of botulinum toxin in functional urology and LUTDs.
517   $aApplication of Botulinum Neurotoxin in Lower Urinary Tract Dysfunctions
606   $aBotulinum toxin
615  0$aBotulinum toxin.
676   $a615.329364
702   $aKuo$b Hann-Chorng
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910734347803321
996   $aApplication of Botulinum Neurotoxin in Lower Urinary Tract Dysfunctions$93421500
997   $aUNINA